Amanda Corbel
Manager, Communications Office
Email amanda.corbel@nih.gov or call 301-228-4489 for all media related questions.
Biotech Connector presents immunotherapeutic strategies for an HIV functional cure
HIV/AIDS researchers presented at the August Biotech Connector about progress toward a functional cure for HIV.POSTED: 9/4/2026
Interdisciplinary team collaboration brings new TMA resource to researchers
Scientists developed and released the first publicly available tissue microarray panel for the NCI Patient-Derived Models Repository.POSTED: 9/3/2026
Technology Showcase returns for its 9th year
Join on Sept. 9 for educational and networking opportunities centered around biotech.POSTED: 8/26/2026
Rethinking rare disease: How the ART Initiative is connecting genomics, the clinic, and the lab bench for RASopathies
The NCI ART Initiative is making headway in better understanding RASopathies and driving new therapies through cross-institutional collaboration.POSTED: 8/10/2026
Uncommon testing capability supports CDC investigation into KSHV-infected organ transplants
Viral Oncology Section’s specialized testing capability supports CDC investigation into rise in Kaposi sarcoma disease in solid organ transplant recipients.POSTED: 8/6/2026
Team cuts one to two-year vaccine production timeline to fewer than 100 days
Vaccine Clinical Materials Program developed a new workflow to produce ready-for-testing vaccines in 13 weeks rather than the conventional 12 to 24 month timeline.POSTED: 7/30/2026
Reproducibility in Science 2026
Scientists share key takeaways from the Reproducibility in Science Symposium, emphasizing important highlights for RAS researchers.POSTED: 7/27/2026
Reproducibility symposium met ‘highest expectations,’ laid plans for more robust science
Reproducibility in Science Symposium brought interdisciplinary crowd together to discuss elevating standards to strengthen research.POSTED: 7/22/2026
Genetic classification of cervical cancer leads to experimental targeted treatment
Scientists have found a new way to sort cervical tumors by their DNA, leading to more precise, personalized treatment options.POSTED: 7/16/2026
A defining moment for RAS medicine: Daraxonrasib delivers historic Phase 3 results in pancreatic cancer
Phase 3 study provides compelling evidence that direct RAS inhibition can translate into meaningful clinical benefit.POSTED: 6/16/2026
Looking for more?
Explore our scientific publications
Our researchers publish hundreds of papers each year in various peer-reviewed journals, including Science, Nature, and The New England Journal of Medicine.